top of page
< Back

Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction

JACC: Basic to Translational Science

September 14, 2022

O'Brien, Kevin


The mitochondrial dysfunction characteristic of heart failure (HF) is associated with changes in intracellular nicotinamide adenine dinucleotide (NAD+) and NADH levels. Raising NAD+ levels with the NAD+ precursor, nicotinamide riboside (NR), may represent a novel HF treatment. In this 30-participant trial of patients with clinically stable HF with reduced ejection fraction, NR, at a dose of 1,000 mg twice daily, appeared to be safe and well tolerated, and approximately doubled whole blood NAD+ levels...

bottom of page